(Q36797841)

16 August 2017

1 reference

title

Hepatitis C virus genetic variability in patients undergoing antiviral therapy (English)

1 reference

16 August 2017

1 reference

1 reference

3

Gonzalo Moratorio

1 reference

16 August 2017

Juan Cristina

1

1 reference

16 August 2017

María del Pilar Moreno

series ordinal

2

1 reference

16 August 2017

publication date

20 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

127

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

185-194

1 reference

Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

PAQ: Partition Analysis of Quasispecies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Hepatitis C virus transmission from an anesthesiologist to a patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Ribavirin's antiviral mechanism of action: lethal mutagenesis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

RNA virus error catastrophe: direct molecular test by using ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Antiviral strategy on the horizon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Quasispecies Structure and Persistence of RNA Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Three broad modalities in the natural history of vertically acquired hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Evolution of hepatitis C virus quasispecies immediately following liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Evolution of hepatitis C virus quasispecies in children with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Glycosylation of hepatitis C virus envelope proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Analysis of mutations within the 5' untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Selective transmission of hepatitis C virus in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

The Los Alamos hepatitis C sequence database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

cis-acting RNA signals in the NS5B C-terminal coding sequence of the hepatitis C virus genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Hepatitis C virus NS5A: tales of a promiscuous protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Hepatitis C virus population dynamics during infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

The nature of interferon-alpha resistance in hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Monitoring sequence space as a test for the target of selection in viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Hepatitis C virus mutation affects proteasomal epitope processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Ribavirin causes error catastrophe during Hantaan virus replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Hepatitis C vaccines: Inducing and challenging memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Genetic diversity and evolution of hepatitis C virus--15 years on

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Relation between viral fitness and immune escape within the hepatitis C virus protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Hepatitis C virus NS5A protein--a master regulator?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Mechanisms of action of ribavirin in antiviral therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Strategies for hepatitis C therapeutic intervention: now and next

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

7 January 2021

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

7 January 2021

Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

7 January 2021

A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

7 January 2021

Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.02.023

7 January 2021

10.1016/J.VIRUSRES.2007.02.023

Identifiers

DOI

1 reference

16 August 2017

1 reference